TW202323278A - 使用抗硬骨抑素抗體治療成骨不全之方法 - Google Patents

使用抗硬骨抑素抗體治療成骨不全之方法 Download PDF

Info

Publication number
TW202323278A
TW202323278A TW111137296A TW111137296A TW202323278A TW 202323278 A TW202323278 A TW 202323278A TW 111137296 A TW111137296 A TW 111137296A TW 111137296 A TW111137296 A TW 111137296A TW 202323278 A TW202323278 A TW 202323278A
Authority
TW
Taiwan
Prior art keywords
sclerostatin
antibody
seq
amino acid
acid sequence
Prior art date
Application number
TW111137296A
Other languages
English (en)
Chinese (zh)
Inventor
阿拉斯泰爾 麥金農
阿倫 米斯特里
艾摩 凱基斯
麥可 奧明斯基
Original Assignee
英商米雷奧生物製藥３公司
美商超基因克斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商米雷奧生物製藥３公司, 美商超基因克斯製藥公司 filed Critical 英商米雷奧生物製藥３公司
Publication of TW202323278A publication Critical patent/TW202323278A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW111137296A 2021-09-30 2022-09-30 使用抗硬骨抑素抗體治療成骨不全之方法 TW202323278A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163250918P 2021-09-30 2021-09-30
US63/250,918 2021-09-30
US202263374982P 2022-09-08 2022-09-08
US63/374,982 2022-09-08

Publications (1)

Publication Number Publication Date
TW202323278A true TW202323278A (zh) 2023-06-16

Family

ID=85783647

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111137296A TW202323278A (zh) 2021-09-30 2022-09-30 使用抗硬骨抑素抗體治療成骨不全之方法

Country Status (9)

Country Link
US (1) US20250011407A1 (https=)
EP (1) EP4408884A4 (https=)
JP (1) JP2024536106A (https=)
KR (1) KR20240082380A (https=)
AU (1) AU2022357544A1 (https=)
CA (1) CA3233220A1 (https=)
MX (1) MX2024003828A (https=)
TW (1) TW202323278A (https=)
WO (1) WO2023056355A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025212547A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Methods of treating osteogenesis imperfecta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517672A (ja) * 2008-03-24 2011-06-16 アボツト・バイオテクノロジー・リミテツド 骨損失を治療するための方法及び組成物
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
KR20190037261A (ko) * 2016-08-08 2019-04-05 암젠 인크 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
US10961305B2 (en) * 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
GB201810746D0 (en) * 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist

Also Published As

Publication number Publication date
JP2024536106A (ja) 2024-10-04
EP4408884A2 (en) 2024-08-07
AU2022357544A1 (en) 2024-04-11
CA3233220A1 (en) 2023-04-06
MX2024003828A (es) 2024-05-10
US20250011407A1 (en) 2025-01-09
WO2023056355A2 (en) 2023-04-06
EP4408884A4 (en) 2025-04-23
KR20240082380A (ko) 2024-06-10
WO2023056355A3 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
US12582712B2 (en) Method of making anti-pro/latent myostatin antibodies
US11925683B2 (en) Compositions for making and using anti-Myostatin antibodies
JP6353500B2 (ja) Ｄｋｋ１抗体およびその使用方法
TW202323278A (zh) 使用抗硬骨抑素抗體治療成骨不全之方法